Update on LEQEMBI Investigational Subcutaneous Formulation TOKYO, Oct. 15, 2023 /PRNewswire/ — Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer’s disease (AD)…